• Drostanolone Propionate 100 mg
• Drostanolone Enanthate 200 mg

PHARMAMIX M300 – PHARMACOM LABS

1 vial x 10 ml x 300 mg/ml

Carrier: Grapeseed Oil

PHARMAMIX M300 is a compound comprising two drostanolone esters, propionate, and enanthate, meticulously formulated to deliver a rapid yet prolonged release of drostanolone. Tailored for extended cycles, this blend ensures the development of high-quality lean muscle mass, creating a dense appearance while minimizing subcutaneous water retention—a common issue with longer esters.

It synergizes well with testosterone and trenbolone blends, such as PHARMASUST 300, 500, PHARMA 3TREN, as well as long testosterone and trenbolone esters like PHARMATEST E300, E500, C250; PHARMATREN E200, H100. A similar stack is featured in our latest development, PHARMAMIX 6, which has achieved considerable success in sales, paralleling the popularity of PHARMAMIX 2.

Drostanolone, first described in 1959 and developed by Syntex, entered the market in 1970 under the trade name Masteron. Approved by the FDA for the treatment of inoperable breast cancer in climacteric women, its medical applications extended globally.

Effects and Uses:

• A derivative of dihydrotestosterone (DHT), Masteron exhibits strong anabolic properties with anti-estrogenic traits.
• Ideal for cutting cycles, Masteron is most effective when used by individuals at an exceptionally lean state, showcasing its muscle density, relief, and definition-enhancing abilities.
• Exhibits a moderate diuretic effect, reducing water retention, and contributing to improved muscle density.
• Known for its lipolytic effect, a Masteron cycle can lead to a reduction in body fat by 5-7%, making it suitable for track and field athletes and bodybuilders aiming to stay within specific weight classes.
• Limited bulking potential compared to other steroids, as it does not aromatize, shows anti-estrogenic traits, and binds to aromatase rather than other substrates.
• Differentiates from stanozolol with a lack of side effects such as increased tendon brittleness, joint fluid dryness, and adverse impacts on blood cholesterol.

Safety Considerations:

• For individuals choosing between drostanolone and stanozolol for a cutting cycle, drostanolone is considered a more reasonable and safer option.
• The compound’s safety and efficacy are contingent on adherence to recommended dosage and cycle duration guidelines.

Dosage Instructions:

• It is crucial to seek guidance from qualified healthcare professionals to determine the appropriate dosage based on individual factors.
• Emphasis on a gradual buildup and reduction in dosage is recommended to optimize safety and efficacy during the cycle.